This is a Validated Antibody Database (VAD) review about human NY ESO 1, based on 35 published articles (read how Labome selects the articles), using NY ESO 1 antibody in all methods. It is aimed to help Labome visitors find the most suited NY ESO 1 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
NY ESO 1 synonym: CT6.1; CTAG; CTAG1; ESO1; LAGE-2; LAGE2B; NY-ESO-1; cancer/testis antigen 1; New York esophageal squamous cell carcinoma 1; autoimmunogenic cancer/testis antigen NY-ESO-1; cancer antigen 3; cancer/testis antigen 6.1; l antigen family member 2

Invitrogen
mouse monoclonal (E978)
  • western blot; human; 1:200; loading ...; fig s7
In order to test if AML patients treated decitabine have induced expression of cancer testis antigens, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in western blot on human samples at 1:200 (fig s7). Oncotarget (2016) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; fig s1
  • western blot; human; 1:1000; fig 2b
In order to use 5-aza-2'-deoxycytidine to upregulate NY-ESO-1 expression by tumor cells, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in flow cytometry on human samples (fig s1) and in western blot on human samples at 1:1000 (fig 2b). PLoS ONE (2015) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:25
In order to investigate NY-ESO-1 in mesenchymal tumors, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in immunohistochemistry - paraffin section on human samples at 1:25. Mod Pathol (2015) ncbi
mouse monoclonal (E978)
  • western blot; human; 1:200; fig 1
In order to investigate the effect of SGI-110 on cancer testis antigen gene-regulated expression, Invitrogen NY ESO 1 antibody (Invitrogen, 35-6200) was used in western blot on human samples at 1:200 (fig 1). Leuk Res (2014) ncbi
mouse monoclonal (E978)
  • immunohistochemistry; human; tbl 1
In order to report enhanced anticancer immunity using dendritic cells to present endocytosed material and initiate T cell immunity, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in immunohistochemistry on human samples (tbl 1). Sci Transl Med (2014) ncbi
mouse monoclonal (E978)
  • western blot; human; fig 2
In order to test if demethylating chemotherapy increases the expression of cancer specific antigens, Invitrogen NY ESO 1 antibody (Invitrogen, clone E978) was used in western blot on human samples (fig 2). Tumour Biol (2014) ncbi
mouse monoclonal (E978)
  • immunocytochemistry; human
Invitrogen NY ESO 1 antibody (Zymed Laboratories, E978) was used in immunocytochemistry on human samples . J Immunol (2014) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 5
In order to assess the therapeutic value of DCs pulsed with NY ESO 1 to treat hepatocellular carcinoma, Invitrogen NY ESO 1 antibody (Zymed Laboratories, E978) was used in immunohistochemistry - paraffin section on human samples (fig 5). Int J Mol Med (2013) ncbi
mouse monoclonal (E978)
  • immunohistochemistry; human; fig 1
In order to discuss how to select appropriate target antigens for immunotherapy for the treatment of metastatic cancer, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in immunohistochemistry on human samples (fig 1). Clin Cancer Res (2013) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
  • western blot; human; fig 2
In order to determine the prevalence and biologic relevance of MAGE-C1/CT7 and other antigens using ovarian cancer samples, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2) and in western blot on human samples (fig 2). Virchows Arch (2013) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 1
In order to correlate NY-ESO-1 and the recurrence of hepatocellular carcinoma following surgery, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in immunohistochemistry - paraffin section on human samples (fig 1). Oncol Lett (2012) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 5
In order to report that re-directed effector- and central memory T cells specifically recognize tumor cells in vitro and in vivo, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples (fig 5). Gene Ther (2013) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; fig 4
In order to investigate the efficacy of the adoptive cell transfer protocol for melanoma patients, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in flow cytometry on human samples (fig 4). Cancer Immunol Immunother (2012) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 5
In order to test if gamma-radiation increases expression of cancer-testis antigens and MHC-I, thus promotes efficient immunological control, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples (fig 5). PLoS ONE (2011) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
In order to assess cancer-testis antigen in prostate cancer samples, Invitrogen NY ESO 1 antibody (ZYMED, E978) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). PLoS ONE (2011) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 5
In order to investigate ESO-based immunotherapy in breast cancer patients, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in immunohistochemistry - paraffin section on human samples (fig 5). PLoS ONE (2011) ncbi
mouse monoclonal (E978)
  • western blot; human; fig 1
In order to study mechanisms to pharmacologically increase expression of cancer antigens on neuroblastoma, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in western blot on human samples (fig 1). Cancer Immunol Immunother (2011) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; fig s7
In order to characterize glioblastoma multiforme cancer stem cells, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in flow cytometry on human samples (fig s7). Clin Cancer Res (2010) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; fig 4
In order to report that fucoidin enhances the cross-presentation of NY-ESO-1 to T cells, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in flow cytometry on human samples (fig 4). Biochem Biophys Res Commun (2010) ncbi
mouse monoclonal (E978)
  • ELISA; human
In order to test if type II ovarian carcinoma, mutation of p53, and plasma levels of particular cytokines are associated with the generation of p53-specific serum autoantibody responses in patients, Invitrogen NY ESO 1 antibody (Invitrogen, E978) was used in ELISA on human samples . Gynecol Oncol (2009) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1
In order to ascertain the expression of several cancer testis antigens in hepatocellular carcinomas, intrahepatic cholangiocarcinomas, extrahepatic cholangiocarcinomas, and gallbladder carcinomas, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1). Int J Cancer (2009) ncbi
mouse monoclonal (E978)
  • immunohistochemistry; human; 1:200; fig 4
In order to study autoantibodies and tumor-infiltrating T cells in epithelial ovarian cancer, Invitrogen NY ESO 1 antibody (Zymed, 35-6200) was used in immunohistochemistry on human samples at 1:200 (fig 4). PLoS ONE (2008) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; 1:500; fig 2
In order to determine the applicability of a modified, in vitro-transcribed mRNA that encodes a therapeutically relevant tumor antigen to analyze T cell responses in cancer patients, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in flow cytometry on human samples at 1:500 (fig 2). Cancer Immunol Immunother (2009) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 2a
  • immunocytochemistry; human; fig 2f
In order to examine the expression of several cancer-testis antigens in patients with monoclonal gammopathy of undetermined significance, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples (fig 2a) and in immunocytochemistry on human samples (fig 2f). Cancer Sci (2008) ncbi
mouse monoclonal (E978)
  • western blot; human
In order to identify MAD-CT-2 as a novel melanoma cancer-testis antigens, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in western blot on human samples . J Immunother (2007) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1
In order to examine NY-ESO-1 expression in various types of breast cancer, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1). Int J Cancer (2007) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 2
In order to study premalignant lesions for markers of head and neck squamous cell carcinoma, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples (fig 2). Cancer Immunol Immunother (2007) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 3
In order to identify and evaluate cancer-germline genes for therapeutic vaccine targets in various pediatric solid tumors, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples (fig 3). Int J Cancer (2007) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:25; fig 2C
In order to study the therapeutic target potential of GAGE protein in cancers, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples at 1:25 (fig 2C). Br J Cancer (2006) ncbi
mouse monoclonal (E978)
  • flow cytometry; human; fig 4
In order to visualize HLA-peptide presentation for the first time, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in flow cytometry on human samples (fig 4). J Immunol (2006) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to characterize tumor infiltrating lymphocytes from seminoma lesions, Invitrogen NY ESO 1 antibody (Zymed, E978) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Int J Cancer (2006) ncbi
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; fig 4
In order to examine the expression of cancer-testis antigen genes and correlate their expression with pathologic characteristics colorectal cancer patients, Invitrogen NY ESO 1 antibody (Zymed Laboratories, E978) was used in immunohistochemistry - paraffin section on human samples (fig 4). Clin Cancer Res (2005) ncbi
Santa Cruz Biotechnology
mouse monoclonal (E978)
  • western blot; human; fig 1
In order to discuss the role of ubiquitination in MHC class I antigen processing modulation, Santa Cruz Biotechnology NY ESO 1 antibody (Santa Cruz, E978) was used in western blot on human samples (fig 1). J Biol Chem (2016) ncbi
mouse monoclonal (E978)
  • other; human; fig 2
In order to characterize capabilities and potentials of extracellular vesicle (EV) array, Santa Cruz Biotechnology NY ESO 1 antibody (Santa Cruz Biotechnology, sc-53869) was used in other on human samples (fig 2). J Extracell Vesicles (2015) ncbi
Sigma-Aldrich
mouse monoclonal (E978)
  • immunohistochemistry - paraffin section; human; 1:100
  • western blot; human; 1:500
Sigma-Aldrich NY ESO 1 antibody (Sigma-Aldrich, E978) was used in immunohistochemistry - paraffin section on human samples at 1:100 and in western blot on human samples at 1:500. J Clin Invest (2015) ncbi
Articles Reviewed
  1. Golnik R, Lehmann A, Kloetzel P, Ebstein F. Major Histocompatibility Complex (MHC) Class I Processing of the NY-ESO-1 Antigen Is Regulated by Rpn10 and Rpn13 Proteins and Immunoproteasomes following Non-lysine Ubiquitination. J Biol Chem. 2016;291:8805-15 pubmed publisher
  2. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed publisher
  3. Klar A, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. PLoS ONE. 2015;10:e0139221 pubmed publisher
  4. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed publisher
  5. Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, et al. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest. 2015;125:593-606 pubmed publisher
  6. Endo M, de Graaff M, Ingram D, Lim S, Lev D, Briaire de Bruijn I, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol. 2015;28:587-95 pubmed publisher
  7. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014;38:1332-41 pubmed publisher
  8. Dhodapkar M, Sznol M, Zhao B, Wang D, Carvajal R, Keohan M, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6:232ra51 pubmed publisher
  9. Krishnadas D, Bao L, Bai F, Chencheri S, Lucas K. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol. 2014;35:5753-62 pubmed publisher
  10. Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, et al. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014;192:523-32 pubmed publisher
  11. Chen Y, Huang A, Gao M, Yan Y, Zhang W. Potential therapeutic value of dendritic cells loaded with NY?ESO?1 protein for the immunotherapy of advanced hepatocellular carcinoma. Int J Mol Med. 2013;32:1366-72 pubmed publisher
  12. Beard R, Abate Daga D, Rosati S, Zheng Z, Wunderlich J, Rosenberg S, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res. 2013;19:4941-50 pubmed publisher
  13. Zimmermann A, Imig J, Klar A, Renner C, Korol D, Fink D, et al. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. Virchows Arch. 2013;462:565-74 pubmed publisher
  14. Xu H, Gu N, Liu Z, Zheng M, Xiong F, Wang S, et al. NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett. 2012;3:39-44 pubmed
  15. Schuberth P, Jakka G, Jensen S, Wadle A, Gautschi F, Haley D, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013;20:386-95 pubmed publisher
  16. Mazzarella T, Cambiaghi V, Rizzo N, Pilla L, Parolini D, Orsenigo E, et al. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Cancer Immunol Immunother. 2012;61:1169-82 pubmed publisher
  17. Sharma A, Bode B, Wenger R, Lehmann K, Sartori A, Moch H, et al. ?-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE. 2011;6:e28217 pubmed publisher
  18. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE. 2011;6:e21366 pubmed publisher
  19. Hamai A, Duperrier Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE. 2011;6:e21129 pubmed publisher
  20. Bao L, Dunham K, Lucas K. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011;60:1299-307 pubmed publisher
  21. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16:800-13 pubmed publisher
  22. Hu Y, Cheng S, Chan K, Ke Y, Xue B, Sin F, et al. Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells. Biochem Biophys Res Commun. 2010;392:329-34 pubmed publisher
  23. Tsai Turton M, Santillan A, Lu D, Bristow R, Chan K, Shih I, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol. 2009;114:12-7 pubmed publisher
  24. Riener M, Wild P, Soll C, Knuth A, Jin B, Jungbluth A, et al. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer. 2009;124:352-7 pubmed publisher
  25. Milne K, Barnes R, Girardin A, Mawer M, Nesslinger N, Ng A, et al. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. PLoS ONE. 2008;3:e3409 pubmed publisher
  26. Knights A, Nuber N, Thomson C, de la Rosa O, Jager E, Tiercy J, et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother. 2009;58:325-38 pubmed publisher
  27. Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci. 2008;99:720-5 pubmed publisher
  28. Dubovsky J, Albertini M, McNeel D. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. J Immunother. 2007;30:675-83 pubmed
  29. Theurillat J, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer. 2007;120:2411-7 pubmed
  30. Young M, Neville B, Chi A, Lathers D, Boyd Gillespie M, Day T. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2007;56:1077-86 pubmed
  31. Jacobs J, Brasseur F, Hulsbergen van de Kaa C, van de Rakt M, Figdor C, Adema G, et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer. 2007;120:67-74 pubmed
  32. Gjerstorff M, Johansen L, Nielsen O, Kock K, Ditzel H. Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br J Cancer. 2006;94:1864-73 pubmed
  33. Purbhoo M, Sutton D, Brewer J, Mullings R, Hill M, Mahon T, et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol. 2006;176:7308-16 pubmed
  34. Hadrup S, Braendstrup O, Jacobsen G, Mortensen S, Pedersen L, Seremet T, et al. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer. 2006;119:831-8 pubmed
  35. Li M, Yuan Y, Han Y, Liu Y, Yan L, Wang Y, et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 2005;11:1809-14 pubmed